Description: This article highlights member survey results intended to assess the level of support for Society of Actuaries programs.

Description: Presented at May 2005 Spring Meeting. Panelists discuss currently available data standards, forecasts about the future uses of data standards, and standards being adopted by Information Technology departments.

Description: The key tasks of credit risk capital project under CROSS II mainly focus onL(1 )Adjustment of measurement framework; (2) Calibration of risk factors, including both credit spread risk and credit default risk;3)Introduction of concentration risk measurement; (4) Higher requirement on look-through rule.

Description: Presented at May 2005 Spring Meeting. Panelists discuss the importance of actuarial research, how and what to do, researching the literature, statistical tests of significance, writing a research report and how to get published.

Description: Acknowledgments, Copyright, and Title Page. From Group Medical Insurance Large Claims Database Collection and Analysis: Acknowledgments, M-HB97-1.

Description: In this article, the author comments about an exposure draft of a proposed revision of Actuarial Standard of Practice 23 dealing with data quality.

Description: The Life Practice Area seeks input on strategic issues including the timeliness of experience reports, the increasing levels of regulation, defending risk classification, ant the viability of the actuarial profession.

Description: Project Oversight Group. From Group Medical Insurance Large Claims Database Collection and Analysis, M-HB97-1.

Description: Realizing the impact of medical errors on the U.S. health care system, the Health Section commissioned a research project to measure the annual frequency of medical errors and their total measurable direct and indirect cost to the economy.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.